PPI Lawsuit Attorneys

Nexium, Prevacid, and Prilosec linked to deadly kidney diseases!

You may be entitled to compensation

Were you or a loved one prescribed Nexium, Prevacid, or Prilosec to treat stomach ulcers or acid reflux?

You are at risk!

  • Chronic Kidney Disease
  • Kidney failure/renal failure
  • Acute Kidney Injury
  • Acute Interstitial Nephritis
  • Dialysis Treatment
  • Kidney Removal
  • Kidney transplant
  • Death
  • Fractures
  • Pneumonia
  • Difficile infection

If you and your loved one has suffered from any of these devastating injuries after using PPIs such as Prevacid, Prilosec, or Nexium, you may be entitled to compensation. Since 1992, research, case studies, adverse event reports, published studies, and other data have been piling up—they show the frighteningly strong link between PPIs and kidney disease as well as other complications. Clearly, the manufacturers knew about the dangers of its drugs and failed to warn about them.

Don’t we need drugs to improve health and save lives? Don’t they all come with side effects?

While all drugs have a chance of side effects, manufacturers have a duty to make their products reasonably safe. When drugs cannot be made safer, manufacturers have a duty warn patients and doctors about the risks associated with their drugs. This is only fair. This allows drug manufacturers to develop new drugs that can improve health and save lives and permits medicine to advance while allowing doctors and patients to make informed decisions concerning an individual patient’s health. When manufacturers fail to warn about known, significant risks, the balance is skewed in favor of big drug manufacturers and is unfair and unsafe for consumers.

The pharmaceutical industry is a huge, for-profit industry. Revenues topped $415 Billion in 2015 alone. Critics raise ethical concerns over the huge markup and overly-inflated prices of drugs. The industry defends by saying the markup is necessary to fund research and development (R&D) and the advancement of medicine. Yet, 90% of the major drug manufacturers spend less on R&D than on marketing. In 2012, drug companies spent an estimated $3 billion marketing directly to consumers and $24 billion marketing directly to doctors and health care providers. Ana Swanson, Big pharmaceutical companies are spending far more on marketing than on research, the Washington Post (Feb. 11, 2015).

This may seem like an irrationally excessive amount of money to spend on marketing, but it works. Prevacid, Prilosec, and Nexium are some of the most overprescribed medications worldwide. Researchers estimate that 70% of the prescriptions for these drugs are unnecessary. Lazarus, B., et al., Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease, JAMA Intern. Med. (2016).

Even more shocking, research beginning in 1999 discovered that PPIs actually cause the symptoms they are designed to treat. This “rebound acid hypersecretion” is a phenomenon whereby the patient takes the drug to control acid but then causes the body to secrete more acid than before when the patient discontinues the drug. A 2009 study explained that this happens after only 8 weeks:

Acid inhibition with a PPI for 8 weeks induces acid-related symptoms in a significant proportion of asymptomatic subjects when therapy is withdrawn [it is] highly likely that [the same] phenomenon is equally relevant in patients treated long term with PPIs. These results could justify the speculation that PPI dependency could be 1 of the explanations for the rapidly and continuously increasing use of PPIs. Christina Reimer, et al., Gastroenterology (2009).

Why should I contact an attorney? I’ve never sued anyone and I can’t afford an attorney.

  1. You have nothing to lose! We will evaluate your case for free! If you or a loved one has been diagnosed with kidney disease, you and your family have enough to worry about. Let our experienced attorneys and staff worry about whether you have a viable claim. While money cannot replace your health, undo your suffering and heartache, or prevent your future suffering, it can help ease the financial burden on you and your family.
  1. Basic Fairness. If a manufacturer harmed you by selling you a product and it knew its product could harm you, and it failed to warn you, the manufacturer should pay for the damage it caused.
  1. Your health is uniquely yours. Drug manufacturers should have warned you of the risks so you and your doctor could decide whether using the product is worth the risk to your These manufacturers robbed you of your autonomy and your power to decide what health risks you will take. Legal and business experts believe that that manufacturers do not warn about the risks of their products because fewer doctors would prescribe them and fewer customers would purchase them. Manufacturers decided for you that the health risk to your body was worth it to them because they would get less of your money. Ideally, the decision-making would involve the patient and doctor balancing the risks versus the benefits of the drug to the patient’s health. In reality, the drug companies use their marketing machines to blast doctors and patients alike with the benefits of the drug. But, this marketing works. In 2005 alone, doctors wrote over 43 million prescriptions and sales topped 8 billion dollars.
  1. Help bring awareness and help others. As the researchers in a 2006 study published in Clinical Gastroenterology & Hepatology concluded: “Increased awareness might facilitate more rapid diagnosis and management of this potentially reversible condition.” Drug companies have billions of dollars to spend on telling consumers about the advantages of their products. You can help hold drug companies accountable, focus attention on the potential dangers of PPIs, and help prevent others from experiencing the pain you and your family are experiencing.
  1. Contact us today for a free case evaluation. Remember, you have nothing to lose and so much to gain. If we do not get money compensation for you, you owe us nothing! If you don’t get paid, we don’t get paid. All legal fees and costs will be paid out of the money we recover for you.

The first study reporting a link between PPIs and kidney damage was published in 1992, just a few years after the FDA approved the first PPI, Prilosec. In 1992, the American Journal of Medicine published an article about a woman who was admitted to the ER with acute renal failure. The patient was diagnosed with drug-induced acute interstitial nephritis because of omeprazole (Prilosec). The researchers cautioned: “Physicians who prescribe omeprazole [Prilosec] should be aware of the association of acute interstitial nephritis with omeprazole.” Stephen Ruffenach, et al., the American Journal of Medicine (1992). This prophetic warning has been echoed by researchers ever since:

  • 1997-study published by the European Renal Association-European Dialysis and Transplant Association reported cases of kidney failure where the patients developed acute interstitial nephritis shortly after they started taking the PPI omeprazole (Prilosec).
  • 2004-study published in Nephrology Dialysis Transplantation examined cases of Tubulo-Interstitial Nephritis (TIN) and found that 8 out of 14 cases caused by drugs were attributable to the PPIs omeprazole (Prilosec) and lansoprazole (Prevacid). The study concluded: (1) drugs are the most common cause of interstitial nephritis (2) PPIs Prevacid and Prilosec were the drugs most commonly associated with this kidney disease.
  • 2006-PPIs are one of the most prescribed drugs worldwide.
  • 2006-study of 28 cases of biopsy-proven AIN kidney disease in hospitals showed that 18 (64%) were associated with PPI use.
  • 2007-study published in Clinical Nephrology concluded “the PPI drug class is clearly associated with the development of AIN” and “should be suspected as a potential cause.” According to researchers, the studies and case reports from 1992 until 2007 “confirmed the association between omeprazole [Prilosec] and AIN.”
  • By 2009, PPIs had been associated with pneumonia, osteoporosis, vitamin B12 deficiency, colitis, and interstitial nephritis. B.M.R. Spiegel et al., NIH (2009).
  • 2013-study published in concluded: “Patients with a renal disease diagnosis were twice as likely to have used a previous prescription for a PPI” and cautioned “it is necessary for physicians to increase recognition of patient complaints or clinical manifestations of this potentially harmful event in order to prevent further injury.” Donald G. Klesper, et al., BMC Nephrology (2013).
  • 2013-PPIs are the most commonly prescribed drugs worldwide and are perceived as “safe with a low side-effect profile,” yet kidney disease “is being increasingly recognized as a complication of PPIs” and is thought to be a common effect of PPIs.” The symptoms of AIN are non-specific and PPI induced AIN “is likely to be under recognized and untreated.” K. Sampathkmar, et al., Indian Journal of Nephrology (2013).
  • Researchers echoed the prophetic warning of the 1992 researchers: “A high index of suspicion about this condition should prompt the physician to stop the drug, perform a renal biopsy if needed and start steroid therapy for halting a progressive renal disease.” K. Sampathkmar, et al., Indian Journal of Nephrology (2013).
  • 2014-A nationwide study found an increased risk of kidney disease with PPI use and current PPI use has a “significantly increased risk” of kidney disease resulting in hospitalization when compared to past use. Mei-Ling Blank, et al., International Society of Nephrology (2014). This suggests that some of the risks could be mitigated if PPIs are discontinued. This is another example of how vitally important it is to human health that manufacturers warn doctors and patients of these risks. For a patient with signs of kidney disease, stopping the PPI could save the patient from dialysis, kidney transplant, and even death.
  • 2015Another study asserts: “[PPIs] cause interstitial nephritis and are an underappreciated cause of acute kidney injury.” This study found “those who started PPI therapy had an increased risk of acute kidney injury and acute interstitial nephritis. These are potentially reversible conditions that may not be readily attributed to drug treatment. Clinicians should appreciate [these risks during PPI treatment], monitor patients appropriately and discourage the indiscriminate use of these drugs.” Tony Antoniou, et al., CMAJ (2015).
  • 2016- Study finds “PPI use was associated with [chronic kidney disease (CKD)] in all analyses.” PPI users were 50% more likely to develop chronic kidney disease than non-users, even after adjusting for all other differences between the groups. Lazarus, Benjamin, et al., MMBS (2016).
  • Another finding of the Lazarus study: “Twice-daily PPI dosing was associated with a higher risk than once-daily dosing.” This is a “dose-response” is strong evidence of a causal link between PPIs and chronic kidney disease.
  • 2016-yet another study shows a substantially increased risk of was published in the Journal of the American Society of Nephrology and finally caught the attention of the media. The headlines said it all. For example, CNN wrote “Popular medications linked to higher risk of kidney failure,” CBS wrote “Heartburn Drugs Tied to Higher Kidney Disease Risk,” and the New York Times wrote “Study Finds Growing Reason to Be Wary of Some Reflux Drugs.”